Novel methods and strategies in the discovery of TACE inhibitors

Expert Opinion on Drug Discovery

Volumn 8, Issue 2, 2013, Pages 157-181

  Murumkar, Prashant R ^a,b   Giridhar, Rajani ^a   Yadav, Mange Ram ^a  

^a M S UNIVERSITY OF BARODA   (India)

^b Sinhgad Institute of Pharmacy   (India)

Author keywords

Design strategies; Hydroxamates; Non hydroxamates; Rheumatoid arthritis; TACE; TACE inhibitors

Indexed keywords

2 [N (4 METHOXYSULFONYL)(3 PYRIDINYLMETHYL)AMINO] 3 METHYLBUTYROHYDROXAMIC ACID; 3,5 DIMETHYLISOXAZOLE; BETA AMINOHYDROXAMIC ACID DERIVATIVE; BETA BENZAMIDO HYDROXAMATE; BETA SULFONE HYDROXAMATE INHIBITOR; BMX 561392; CIPEMASTAT; DIAZEPINE DERIVATIVE; GAMMA LACTAM HYDROXAMATE; HYDANTOIN; IK 682; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; PRINOMASTAT; THIAZEPINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG;

BINDING SITE; DRUG BINDING; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG WITHDRAWAL; HUMAN; IC 50; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TENDINITIS;

ADAM PROTEINS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84872736716     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2013.744745     Document Type: Review

References (89)

1. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-a from cells. Nature 1997;385:729-33 (Pubitemid 27098094)
2. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992;10:411-52
3. Yang JS, Chun K, Park JE, et al. Structure based optimization of chromen-based TNF-α converting enzyme (TACE) inhibitors on S1' pocket and their quantitative structure-activity relationship (QSAR) study. Bioorg Med Chem 2010;18:8618-29
4. Dasgupta S, Murumkar PR, Giridhar R, et al. Current perspective of TACE inhibitors: a review. Bioorg Med Chem 2009;17:444-59
5. Maini RN, Elliott MJ, Brennan FM, et al. Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA). Clin Exp Immunol 1995;101:207-12
6. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7 (Pubitemid 24317633)
7. Horiuchi T, Mitoma H, Harashima S, et al. Transmembrane TNF-α: structure, function and interaction with anti-TNF agents. Rheumatology 2010;49:1215-28
8. Bahiya MS, Silakari O. Tumor necrosis factor alpha converting enzyme: an encouraging target for various inflammatory disorders. Chem Biol Drug Des 2010;74:415-43
9. Mohler KM, Sleath PR, Fitzner JN, et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 1994;370:218-20 (Pubitemid 24236777)
10. McGeehan GM, Becherer JD, Bast RC, et al. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature 1994;370:558-61 (Pubitemid 24264921)
11. Leung D, Giovanni A, Fairlie DP. Protease inhibitors: current status and future prospectus. J Med Chem 2000;43:305-41 (Pubitemid 30102072)
12. Shrivastava PK, Dastidar SG, Ray A. Chronic obstructive pulmonary disease: role of matrix mettaloprotease and future challenge of drug therapy. Expert Opin Invest Drugs 2007;16:1069-78 (Pubitemid 47074161)
13. Wasserman ZR, Duan JJ, Voss ME, et al. Identification of a selectivity determinant for inhibition of tumor necrosis factor-alpha converting enzyme by comparative modeling. Chem Biol 2003;10:215-23 (Pubitemid 36380278)
14. Aranapakam V, Davis JM, Grosu GT, et al. Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. J Med Chem 2003;46:2376-96 (Pubitemid 36637922)
15. Levin JI, Du MT, DiJoseph JF, et al. The Discovery of Anthranilic Acid-Based MMP Inhibitors. Part 1: SAR of the 3-Position. Bioorg Med Chem Lett 2001;11:235-8 (Pubitemid 32099648)
16. Zask A, Kaplan J, Du XM, et al. Synthesis and SAR of diazepine and thiazepine TACE and MMP inhibitors. Bioorg Med Chem Lett 2005;15:1641-5 (Pubitemid 40312545)
17. Yocum SA, Lopresti-Monow LL, Reeves LM, et al. MMP-13 and MMP-1 expression in tissues of normal articular joints. Ann NY Acad Sci 1999;878:583-6 (Pubitemid 29353620)
18. Holmbeck K, Binaco P, Caterina J, et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis and connective tissue disease due to inadequate collagen turnover. Cell 1999;99:81-92 (Pubitemid 29468632)
19. Newton RC, Solomon KA, Covington MB, et al. Biology of TACE inhibition. Ann Rheum Dis 2001;60:25-32
20. Conway JG, Andrews RC, Beaudet B, et al. Inhibition of tumor necrosis factor alpha production and arthritis in rat by GW3333, a dual inhibitor of TNF-α converting enzyme and matrix metalloproteinases. J Pharmacol Exp Ther 2001;298:900-8 (Pubitemid 32761902)
21. Robinson RP, Laird ER, Blake JF, et al. Structure based design and synthesis of a potent matrix metalloproteinase-13 inhibitor based on a pyrrolidinone scaffold. J Med Chem 2000;43:2293-6 (Pubitemid 30431926)
22. Venkatesan AM, Davis JM, Grosu GT, et al. Synthesis and structure-activity relationships of 4-alkynyloxy Phenyl Sulfanyl, Sulfinyl, and Sulfonyl Alkyl hydroxamates as tumor necrosis factor-a converting enzyme and matrix metalloproteinase inhibitors. J Med Chem 2004;47:6255-69 (Pubitemid 39587250)
23. Zhang Y, Xu J, Levin J, et al. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-Nhydroxy-2,2-dimethyl-(3S) thiomorpholine carboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. J Pharmacol Expt Ther 2004;309:348-55 (Pubitemid 38393148)
24. Gilmore JL, King BW, Asakawa N, et al. Synthesis and structure-activity relationship of a novel, non-hydroxamate series of TNF-α converting enzyme inhibitors. Bioorg Med Chem Lett 2007;17:4678-82 (Pubitemid 47058928)
25. Cross JB, Duca JS, Kaminski JJ, et al. The active site of a zinc-dependent metalloproteinase influences the computed pKa of ligands coordinated to the catalytic zinc ion. J Am Chem Soc 2002;124:11004-7 (Pubitemid 35025658)
26. Park K, Aplasca A, Du MT, et al. Design and synthesis of butynyloxyphenyl b-sulfone piperidine hydroxamates as TACE inhibitors. Bioorg Med Chem Lett 2006;16:3927-31 (Pubitemid 43903225)
27. Condon JS, Joseph-McCarthy D, Levin JI, et al. Identification of potent and selective TACE inhibitors via the S1 pocket. Bioorg Med Chem Lett 2007;17:34-9 (Pubitemid 44959992)
28. Huang A, Joseph-McCarthy D, Lovering F, et al. Structure-based design of TACE selective inhibitors: manipulations in the S10-S30 pocket. Bioorg Med Chem 2007;15:6170-81 (Pubitemid 47088960)
29. Duan JJW, Chen L, Wasserman ZR, et al. Inhibition of potent and selective TACE inhibitors via the S1 pocket. J Med Chem 2002;45:4954-7
30. Qian M, Bai SA, Brogdon B, et al. Pharmacokinetics and pharmacodynamics of DPC ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a potent and selective inhibitor of tumor necrosis factor alpha-converting enzyme in rodents, dogs, chimpanzees, and humans. Drug Metab Dispos 2007;35:1916-25 (Pubitemid 47481587)
31. Moss ML, Tavron LS, Nedelman R, et al. Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol 2008;4:300-9 (Pubitemid 351791441)
32. Xue CB, He X, Roderick J, et al. Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-α converting enzyme inhibitors. Part 1: lead identification. Bioorg Med Chem Lett 2003;13:4293-7 (Pubitemid 37490806)
33. Xue CB, He X, Roderick J, et al. Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-α converting enzyme inhibitors. Part 2: lead optimization. Bioorg Med Chem Lett 2003;13:4299-04 (Pubitemid 37490807)
34. Xue CB, Chen XT, He X, et al. Synthesis and structure-activity relationship of a novel sulfone series of TNF-α converting enzyme inhibitors. Bioorg Med Chem Lett 2004;14:4453-9 (Pubitemid 39043966)
35. Duan JJ, Chen L, Lu Z, et al. Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors. Bioorg Med Chem Lett 2008;18:241-6
36. Ott GR, Asakawa N, Lu Z, et al. a,b-Cyclic-b-benzamido hydroxamic acids: Novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-α converting enzyme (TACE). Bioorg Med Chem Lett 2008;18:694-9
37. Ott GR, Asakawa N, Liu RQ, et al. a,b-Cyclic-β-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-a converting enzyme (TACE). Bioorg Med Chem Lett 2008;18:1288-92 (Pubitemid 351226547)
38. Lu Z, Ott GR, Anand R, et al. Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-a converting enzyme (TACE): discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1' substituents. Bioorg Med Chem Lett 2008;18:1958-62 (Pubitemid 351380894)
39. Ott GR, Asakawa N, Lu Z, et al. Potent, exceptionally selective, orally bioavailable inhibitors of TNF-α Converting Enzyme (TACE): novel 2-substituted-1H-benzo [d]imidazol-1-yl)methyl)benzamide P1' substituents. Bioorg Med Chem Lett 2008;18:1577-82 (Pubitemid 351318259)
40. Sengupta P, Puria CS, Chokshi HA, et al. Synthesis, preliminary biological evaluation and molecular modeling of some new heterocyclic inhibitors of TACE. Eur J Med Chem 2011;46:5549-55
41. Zask A, Kaplan J, Du XM, et al. Synthesis and SAR of diazepine and thiazepine TACE and MMP inhibitors. Bioorg Med Chem Lett 2005;15:1641-5 (Pubitemid 40312545)
42. Cherney RJ, Duan JJ, Voss ME, et al. Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-a converting enzyme inhibitors. J Med Chem 2003;46:1811-23 (Pubitemid 36532225)
43. Gilmore JL, King BW, Harris C, et al. Synthesis and structure-activity relationship of a novel, achiral series of TNF-α converting enzyme inhibitors. Bioorg Med Chem Lett 2006;16:2699-04
44. Chen XT, Ghavimi B, Corbett RL, et al. A new 4-(2-methylquinolin-4- ylmethyl) phenyl P1' group for the b-amino hydroxamic acid derived TACE inhibitors. Bioorg Med Chem Lett 2007;17:1865-70 (Pubitemid 46367677)
45. Chun K, Park SK, Kim HM, et al. Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem 2008;16:530-5
46. Guo Z, Orth P, Wong SC, et al. Discovery of novel spirocyclopropyl hydroxamate and carboxylate compounds as TACE inhibitors. Bioorg Med Chem Lett 2009;19:54-7
47. Zhu Z, Mazzola R, Sinning L, et al. Discovery of novel hydroxamates as highly potent tumor necrosis factor-a converting enzyme inhibitors: part I discovery of two binding modes. J Med Chem 2008;51:725-36 (Pubitemid 351304682)
48. Park K, Aplasca A, Du MT, et al. Design and synthesis of butynyloxyphenyl b-sulfone piperidine hydroxamates as TACE inhibitors. Bioorg Med Chem Lett 2006;16:3927-31 (Pubitemid 43903225)
49. Condon JS, Joseph-McCarthy D, Levin JI, et al. Identification of potent and selective TACE inhibitors via the S1 pocket. Bioorg Med Chem Lett 2007;17:34-9 (Pubitemid 44959992)
50. Huan A, McCarthy DJ, Lovering F, et al. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket. Bioorg Med Chem 2007;15:6170-81 (Pubitemid 47088960)
51. Lombart HG, Feyfant E, Joseph-McCarthy D, et al. Design and synthesis of 3,3-piperidine hydroxamate analogs as selective TACE inhibitors. Bioorg Med Chem 2007;15:4333-7 (Pubitemid 47021386)
52. DasGupta S, Murumkar PR, Giridhar R, et al. Studies on novel 2-imidazolidinones and tetrahydropyrimidin-2(1H)-ones as potential TACE inhibitors: design, synthesis, molecular modeling, and preliminary biological evaluation. Bioorg Med Chem 2009;17:3604-17
53. Gilmore JL, King BW, Asakawa N, et al. Synthesis and structure-activity relationship of a novel, non-hydroxamate series of TNF-α converting enzyme inhibitors. Bioorg Med Chem Lett 2007;17:4678-82 (Pubitemid 47058928)
54. Puerta DT, Lewis JA, Cohen SMJ. New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups. Am Chem Soc 2004;126:8388-9 (Pubitemid 38917956)
55. Kamei N, Tanaka T, Kawai K, et al. Reverse hydroxamate-based selective TACE inhibitors. Bioorg Med Chem Lett 2004;14:2897-900 (Pubitemid 38569759)
56. Le GT, Abbenante G. Inhibitors of TACE and Caspase-1 as anti-inflammatory drugs. Curr Med Chem 2005;12:2963-77 (Pubitemid 41672486)
57. Robinowitz MH, Andrews RC, Becherer JD, et al. Design of selective and soluble inhibitors of tumor necrosis factor-a converting enzyme (TACE). J Med Chem 2001;44:4252-67 (Pubitemid 33095331)
58. Kamei N, Tanaka T, Kawai K, et al. Reverse hydroxamate-based selective TACE inhibitors. Bioorg Med Chem Lett 2004;14:2897-900 (Pubitemid 38569759)
59. Doggrell SA. TACE inhibition a new approach to treating inflammation. Expert Opin Investig Drugs 2002;11:1003-6 (Pubitemid 34732718)
60. Duan JJ, Chen L, Lu Z, et al. Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-a converting enzyme (TACE). Bioorg Med Chem Lett 2007;17:266
61. Sheppeck JE, Gilmore JL, Yang A, et al. Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-a converting enzyme (TACE). Bioorg Med Chem Lett 2007;17:1413-17 (Pubitemid 46240831)
62. Gilmore JL, King BW, Asakawa N, et al. Synthesis and structure-activity relationship of a novel, non-hydroxamate series of TNF-α converting enzyme inhibitors. Bioorg Med Chem Lett 2007;17:4678-82 (Pubitemid 47058928)
63. Sheppeck JE, Tebben A, Gilmore JL, et al. A molecular modeling analysis of novel non-hydroxamate inhibitors of TACE. Bioorg Med Chem Lett 2007;17:1408-12 (Pubitemid 46240837)
64. Freskos JN, Mischke BV, Decrescenzo GA, et al. Discovery of novel series of selective matrix metalloproteinase inhibitors: identification of the gamma-sulfone thiols. Bioorg Med Chem Lett 1999;9:943-8 (Pubitemid 29179885)
65. Rao GB, Bandarage UK, Wang T, et al. Novel thiol-based TACE inhibitors: rational design, synthesis, and SAR of thiol-containing aryl sulphonamides. Bioorg Med Chem Lett 2007;17:2250-3 (Pubitemid 46484304)
66. Bandarage UK, Wang T, Come JH, et al. Novel thiol-based TACE inhibitors. Part 2: rational design, synthesis, and SAR of thiol-containing aryl sulfones. Bioorg Med Chem Lett 2008;18:44-8
67. Sheppeck JE, Tebben A, Gilmore JL, et al. A molecular modeling analysis of novel non-hydroxamate inhibitors of TACE. Bioorg Med Chem Lett 2007;17:1408-12 (Pubitemid 46240837)
68. Sheppeck JE, Gilmore JL, Tebben A, et al. Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-a converting enzyme (TACE). Bioorg Med Chem Lett 2007;17:2769-74 (Pubitemid 46636261)
69. Yu W, Guo Z, Orth P, et al. Discovery and SAR of hydantoin TACE inhibitors. Bioorg Med Chem Lett 2010;20:1877-80
70. Girijavallabhan VM, Chen L, Dai C, et al. Novel TNF-α converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases. Bioorg Med Chem Lett 2010;20:7283-7
71. Rosner KE, Guo Z, Orth P, et al. The discovery of novel tartrate-based TNF-α converting enzyme (TACE) inhibitors. Bioorg Med Chem Lett 2010;20:1189-93
72. Li D, Popovici-Muller J, Belanger DB, et al. Structure and activity relationships of tartrate-based TACE inhibitors. Bioorg Med Chem Lett 2010;20:4812-15
73. Dai C, Li D, Popovici-Muller J, et al. 2-(2-Aminothiazol-4-yl) pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors. Bioorg Med Chem Lett 2011;21:3172-5
74. Guo Z, Orth P, Wonga SC, et al. Discovery of novel spirocyclopropyl hydroxamate and carboxylate compounds as TACE inhibitors. Bioorg Med Chem Lett 2009;19:54-7
75. Park K, Gopalsamy A, Aplasca A, et al. Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-α converting enzyme (TACE) inhibitors. Bioorg Med Chem 2009;17:3857-65
76. Nissen P, Hansen J, Ban N, et al. The structural basis of ribosome activity in peptide bond synthesis. Science 2000;289:920-30 (Pubitemid 30659940)
77. Wasserman Z, Duan J, Voss M, et al. Identification of a selectivity determinant for inhibition of tumor necrosis factor-alpha converting enzyme by comparative modeling. Chem Biol 2003;10:215-23 (Pubitemid 36380278)
78. Duan JJ, Chen L, Wasserman ZR, et al. Discovery of b-Lactam hydroxamic acids as selective inhibitors of tumor necrosis factor-a converting enzyme: design, synthesis, and structure-activity relationships. J Med Chem 2002;45:4954-7 (Pubitemid 35278690)
79. Niu X, Umland S, Ingram R, et al. IK682, a tight binding inhibitor of TACE. Arch. Biochem Biophys 2006;451:43-50
80. Lukacova V, Zhang Y, Kroll DM, et al. A comparison of the binding sites of matrix metalloproteinases and tumor necrosis factor-alpha converting enzyme: implications for selectivity. J Med Chem 2005;48:2361-70 (Pubitemid 40516430)
81. Zhao Y, Feng W, Yang Y, et al. Comparision of properties of tumor necrosis factor alfa converting enzyme (TACE) and some matrix metalloproteases(MMP's) in catalytic domain. J Huazhong Univ Sci Technolog Med Sci 2006;26:637-9
82. Bahia M, Silakari O. Generation of selective TACE inhibitors: ligand and structure based molecular modeling, virtual screening, counter pharmacophore screening to get selective molecules. QSAR Comb. Sci 2009;28:1317-33
83. Bahia M, Silakari O. Strategy for generation of new TACE inhibitors: pharmacophore and counter pharmacophore modeling to remove non-selective hits. Med Chem Res 2011;20:760-8
84. Bahia M, Gade S, Mahmood S, et al. Anthranilate derivatives as TACE inhibitors: docking based CoMFA and CoMSIA analyses. J. Mol. Model 2011;17:9-19
85. Feng W, Zhao Y, Huang W, et al. Molecular modeling and biological effects of peptidomimetic inhibitors of TACE activity. J Enzyme Inhib Med Chem 2010;25:459-66
86. Murumkar PR, Giridhar R, Yadav MR. 3D-QSAR studies on Benzothiadizapin Hydroxamate as Inhibitors of TNF-α converting enzyme. Chem Biol Drug Des 2008;71:363-73
87. Murumkar PR, DasGupta S, Zambre VP, et al. Development of Predictive 3D-QSAR CoMFA and CoMSIA Models for b-aminohydoxamic acid-derived TNF-α converting enzyme inhibitors. Chem Biol Drug Des 2009;73:97-107
88. Murumkar PR, DasGupta S, Zambre VP, et al. Development of predictive pharmacophore model for in silico Screening and 3D QSAR for lead optimization for designing of potent tumor necrosis factor alpha converting enzyme inhibitors. J Comput Aided Mol Des 2010;24:143-56
89. Murumkar PR, Dasgupta S, Chandani SR, et al. Novel TACE inhibitors in drug discovery: a review of patented compounds. Expert Opin Ther Pat 2010;20:31-57